165 related articles for article (PubMed ID: 27457663)
1. Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports.
Alberts P; Olmane E; Brokāne L; Krastiņa Z; Romanovska M; Kupčs K; Isajevs S; Proboka G; Erdmanis R; Nazarovs J; Venskus D
APMIS; 2016 Oct; 124(10):896-904. PubMed ID: 27457663
[TBL] [Abstract][Full Text] [Related]
2. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study.
Doniņa S; Strēle I; Proboka G; Auziņš J; Alberts P; Jonsson B; Venskus D; Muceniece A
Melanoma Res; 2015 Oct; 25(5):421-6. PubMed ID: 26193376
[TBL] [Abstract][Full Text] [Related]
3. The advent of oncolytic virotherapy in oncology: The Rigvir® story.
Alberts P; Tilgase A; Rasa A; Bandere K; Venskus D
Eur J Pharmacol; 2018 Oct; 837():117-126. PubMed ID: 30179611
[TBL] [Abstract][Full Text] [Related]
4. A Case of Stage IV Chromophobe Renal Cell Carcinoma Treated with the Oncolytic ECHO-7 Virus, Rigvir®.
Ismailov Z; Rasa A; Bandere K; Brokāne L; Tilgase A; Olmane E; Nazarovs J; Alberts P
Am J Case Rep; 2019 Jan; 20():48-52. PubMed ID: 30635548
[TBL] [Abstract][Full Text] [Related]
5. Stage IIA Skin Melanoma Treatment With ECHO-7 Oncolytic Virus Rigvir.
Čēma I; Kleina R; Doniņa S; Isajevs S; Zablocka T; Rasa A; Alberts P
Perm J; 2022 Sep; 26(3):139-144. PubMed ID: 35950985
[TBL] [Abstract][Full Text] [Related]
6. A progressive stage IIIB melanoma treated with oncolytic ECHO-7 virus: A case report.
Sorokins V; Tilgase A; Olmane E; Isajevs S; Zablocka T; Rasa A; Alberts P
SAGE Open Med Case Rep; 2020; 8():2050313X20934978. PubMed ID: 32637110
[TBL] [Abstract][Full Text] [Related]
7. Effect of oncolytic ECHO-7 virus strain Rigvir on uveal melanoma cell lines.
Tilgase A; Grīne L; Blāķe I; Borodušķis M; Rasa A; Alberts P
BMC Res Notes; 2020 Apr; 13(1):222. PubMed ID: 32299493
[TBL] [Abstract][Full Text] [Related]
8. Treatment of a stage III rima glottidis patient with the oncolytic virus Rigvir: A retrospective case report.
Proboka G; Rasa A; Olmane E; Isajevs S; Tilgase A; Alberts P
Medicine (Baltimore); 2019 Nov; 98(45):e17883. PubMed ID: 31702662
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic virus preclinical toxicology studies.
Rasa A; Alberts P
J Appl Toxicol; 2023 May; 43(5):620-648. PubMed ID: 36299168
[TBL] [Abstract][Full Text] [Related]
10. Cytolytic Properties and Genome Analysis of Rigvir
Hietanen E; Koivu MKA; Susi P
Viruses; 2022 Mar; 14(3):. PubMed ID: 35336934
[TBL] [Abstract][Full Text] [Related]
11. ECHO-7 oncolytic virus Rigvir® in an adjuvant setting for stage I uveal melanoma; A retrospective case report.
Jaunalksne I; Brokāne L; Petroška D; Rasa A; Alberts P
Am J Ophthalmol Case Rep; 2020 Mar; 17():100615. PubMed ID: 32072076
[TBL] [Abstract][Full Text] [Related]
12. Effect of the oncolytic ECHO-7 virus Rigvir® on the viability of cell lines of human origin
Tilgase A; Patetko L; Blāķe I; Ramata-Stunda A; Borodušķis M; Alberts P
J Cancer; 2018; 9(6):1033-1049. PubMed ID: 29581783
[No Abstract] [Full Text] [Related]
13. Multimodality Treatment of a Colorectal Cancer Stage IV Patient with FOLFOX-4, Bevacizumab, Rigvir Oncolytic Virus, and Surgery.
Tilgase A; Olmane E; Nazarovs J; Brokāne L; Erdmanis R; Rasa A; Alberts P
Case Rep Gastroenterol; 2018; 12(2):457-465. PubMed ID: 30283278
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.
Babiker HM; Riaz IB; Husnain M; Borad MJ
Oncolytic Virother; 2017; 6():11-18. PubMed ID: 28224120
[TBL] [Abstract][Full Text] [Related]
15. Reply to Alberts, P. Comment on "Hietanen et al. Cytolytic Properties and Genome Analysis of Rigvir
Hietanen E; Susi P
Viruses; 2022 Sep; 14(9):. PubMed ID: 36146884
[TBL] [Abstract][Full Text] [Related]
16. Reduced angiogenic gene expression in morbillivirus-triggered oncolysis in a translational model for histiocytic sarcoma.
Pfankuche VM; Spitzbarth I; Lapp S; Ulrich R; Deschl U; Kalkuhl A; Baumgärtner W; Puff C
J Cell Mol Med; 2017 Apr; 21(4):816-830. PubMed ID: 27860224
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography/computed tomography evaluation of oncolytic virus therapy efficacy in melanoma.
Franke V; van der Hiel B; van de Wiel BA; Klop WMC; Ter Meulen S; van Akkooi ACJ
Eur J Cancer; 2018 Feb; 90():149-152. PubMed ID: 29224902
[No Abstract] [Full Text] [Related]
18. Japanese Lung Cancer Registry Study: first prospective enrollment of a large number of surgical and nonsurgical cases in 2002.
Sawabata N; Asamura H; Goya T; Mori M; Nakanishi Y; Eguchi K; Koshiishi Y; Okumura M; Miyaoka E; Fujii Y;
J Thorac Oncol; 2010 Sep; 5(9):1369-75. PubMed ID: 20683209
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumour activity of oncolytic reovirus against canine histiocytic sarcoma cells.
Igase M; Shousu K; Fujiki N; Sakurai M; Bonkobara M; Hwang CC; Coffey M; Noguchi S; Nemoto Y; Mizuno T
Vet Comp Oncol; 2019 Jun; 17(2):184-193. PubMed ID: 30761736
[TBL] [Abstract][Full Text] [Related]
20. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.
Chesney J; Awasthi S; Curti B; Hutchins L; Linette G; Triozzi P; Tan MCB; Brown RE; Nemunaitis J; Whitman E; Windham C; Lutzky J; Downey GF; Batty N; Amatruda T
Melanoma Res; 2018 Feb; 28(1):44-51. PubMed ID: 29176501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
